NeoGenomics (NEO) 10-Q 31 Jul 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 24, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	NEO
Entity Registrant Name	NEOGENOMICS INC
Entity Central Index Key	1,077,183
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		60,510,045

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 32,952	$ 33,689
Accounts receivable (net of allowance for doubtful accounts of $4,194 and $4,180 respectively)	21,130	20,475
Inventories	3,416	2,616
Deferred income tax asset, net	821	821
Other current assets	1,282	1,141
Total current assets	59,601	58,742
PROPERTY AND EQUIPMENT (net of accumulated depreciation of $23,069 and $19,822 respectively)	16,286	15,082
INTANGIBLE ASSETS, NET	4,022	4,212
GOODWILL	2,929	2,929
OTHER ASSETS	128	141
TOTAL ASSETS	82,966	81,106
CURRENT LIABILITIES
Accounts payable	6,059	6,294
Accrued compensation	3,940	3,897
Accrued expenses and other liabilities	1,231	1,208
Short-term portion of equipment capital lease obligations	3,895	3,224
Total current liabilities	15,125	14,623
LONG-TERM LIABILITIES
Long-term portion of equipment capital lease obligations	6,153	5,257
Deferred income tax liability, net	821	821
Total long-term liabilities	6,974	6,078
TOTAL LIABILITIES	$ 22,099	$ 20,701
COMMITMENTS AND CONTINGENCIES (SEE NOTE G)
STOCKHOLDERS' EQUITY
Common stock, $.001 par value, (100,000,000 shares authorized; 60,503,996 and 60,242,818 shares issued and outstanding, respectively)	$ 61	$ 60
Additional paid-in capital	81,148	79,751
Accumulated deficit	(20,342)	(19,406)
Total stockholders' equity	60,867	60,405
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 82,966	$ 81,106

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 4,194	$ 4,180
Property and equipment, accumulated depreciation	$ 23,069	$ 19,822
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	60,503,996	60,242,818
Common stock, shares outstanding	60,503,996	60,242,818

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
NET REVENUE	$ 24,370	$ 20,670	$ 47,396	$ 38,852
COST OF REVENUE	13,557	10,431	27,040	19,904
GROSS MARGIN	10,813	10,239	20,356	18,948
OPERATING EXPENSES
General and administrative	7,075	5,870	13,598	10,924
Research and development	803	633	1,471	1,261
Sales and marketing	2,907	3,158	5,821	5,791
Total operating expenses	10,785	9,661	20,890	17,976
INCOME (LOSS) FROM OPERATIONS	28	578	(534)	972
INTEREST AND OTHER EXPENSE - NET	(189)	(253)	(384)	(518)
(LOSS) INCOME BEFORE INCOME TAXES	(161)	325	(918)	454
INCOME TAXES	15	51	19	78
NET (LOSS) INCOME	$ (176)	$ 274	$ (937)	$ 376
NET (LOSS) INCOME PER SHARE - Basic	$ 0	$ 0.01	$ (0.02)	$ 0.01
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - Basic	60,425	49,890	60,352	49,590
NET (LOSS) INCOME PER SHARE - Diluted	$ 0	$ 0.01	$ (0.02)	$ 0.01
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - Diluted	60,425	53,733	60,352	53,551

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (937)	$ 376
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Bad debt expense	1,303	1,814
Amortization of intangibles	190	111
Depreciation and amortization of property and equipment	3,249	2,400
Amortization of debt issue costs		25
Stock-based compensation - options and restricted stock	813	246
Stock-based compensation - warrants	207	35
Changes in assets and liabilities, net:
Accounts receivable, net of write-offs	(1,958)	(1,960)
Inventories	(800)	(315)
Other current assets	(141)	34
Other assets	13	38
Accounts payable and other liabilities	(41)	2,494
NET CASH PROVIDED BY OPERATING ACTIVITIES	1,897	5,298
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(1,180)	(1,966)
NET CASH USED IN INVESTING ACTIVITIES	(1,180)	(1,966)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on credit facility, net		(2,292)
Repayment of capital lease obligations	(1,833)	(1,615)
Issuance of common stock for the exercise of options, warrants and ESPP shares	379	764
NET CASH USED IN FINANCING ACTIVITIES	(1,454)	(3,143)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(737)	189
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	33,689	4,834
CASH AND CASH EQUIVALENTS, END OF PERIOD	32,952	5,023
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest paid	417	498
Income taxes paid	20	170
NON-CASH INVESTING AND FINANCING ACTIVITIES
Equipment leased under capital lease obligations	$ 3,400	$ 3,321

Nature of Business and Basis of

Nature of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	NOTE A — NATURE OF BUSINESS AND BASIS OF PRESENTATION NeoGenomics, Inc., a Nevada corporation (the “Parent” or the “Parent Company”), and its subsidiaries, NeoGenomics Laboratories, Inc., a Florida corporation (“NEO”, “NeoGenomics Laboratories”) and Path Labs LLC., a Delaware Limited Liability Corporation (“Path Logic”) (collectively referred to as “we”, “us”, “our”, “NeoGenomics”, or the “Company”), operates a network of anatomic pathology and certified “high complexity” clinical laboratories in accordance with the federal government’s Clinical Laboratory Improvement Act, as amended (“CLIA”), and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories throughout the United States. The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. These accompanying interim consolidated financial statements include the accounts of the Parent and its subsidiaries. All intercompany transactions and balances have been eliminated in the accompanying interim consolidated financial statements. Certain information and footnote disclosures normally included in the Company’s annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these accompanying interim consolidated financial statements. Accordingly, the accompanying interim consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 3, 2015 and amended on April 30, 2015. The results of operations presented in this quarterly report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited consolidated financial statements include all adjustments and accruals, consisting only of normal recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	6 Months Ended
	Jun. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Guidance	NOTE B — RECENTLY ISSUED ACCOUNTING GUIDANCE Management has determined there has been no recently issued accounting guidance that will have a material impact on the consolidated financial statements.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Acquisitions	NOTE C — ACQUISITIONS On July 8, 2014, NeoGenomics, Laboratories entered into a membership interest purchase agreement with Path Labs, LLC d/b/a Path Logic, a Delaware limited liability company (“Path Logic”), and Path Labs Holdings, LLC, a Delaware limited liability company (“PL Holdings”), whereby the Company acquired all of the outstanding equity ownership interests in Path Logic from PL Holdings for a purchase price (in thousands) of $5,908 (the “Acquisition”). NeoGenomics Laboratories paid the purchase price using cash on hand and borrowings on its revolving credit facility. The following table summarizes the final amounts for the fair values of the assets acquired and liabilities assumed at the acquisition date of July 8, 2014 (in thousands): July 8, 2014 Current assets, including cash and cash equivalents $ 1,722 Property, plant and equipment 577 Identifiable intangible assets – customer relationships 1,930 Long term deposits 28 Goodwill 2,929 Total assets acquired 7,186 Current liabilities (1,180 ) Long-term liabilities (98 ) Net assets acquired $ 5,908 The above estimated fair values of assets acquired and liabilities assumed are based on the information that was available as of the acquisition date to estimate the fair value of assets acquired and liabilities assumed. The measurement period adjustments were complete as of December 31, 2014. Acquired intangible assets of $1.93 million consist of customer relationships which are being amortized over thirteen years. We recorded approximately $37,000 and $74,000 of amortization expense for the three and six months ended June 30, 2015, respectively. The estimated amortization expense related to the acquired intangible assets for each of the five succeeding fiscal years and thereafter as of June 30, 2015 is as follows (in thousands): Year Ending December 31, Remainder of 2015 $ 74 2016 148 2017 148 2018 148 2019 148 2020 148 Thereafter 970 Total $ 1,784 The goodwill arising from the acquisition of Path Logic includes revenue synergies as a result of our existing customers and Path Logic’s customers having access to each other’s testing menus and capabilities. It also arises from the new product lines which Path Logic adds to the Company’s product portfolio. The total amount of goodwill which is expected to be deductible for tax purposes is approximately $3.7 million, which will be amortized on our tax returns over 15 years. The following unaudited pro forma information (in thousands) have been provided for illustrative purposes only and are not necessarily indicative of results that would have occurred had the Acquisition been in effect since January 1, 2013, nor are they necessarily indicative of future results. Three Months Ended Six Months Ended Revenue $ 23,216 $ 43,833 Net (loss) (100 ) (406 ) (Loss) per share Basic $ (0.00 ) $ (0.01 ) Diluted $ (0.00 ) $ (0.01 ) The unaudited pro forma consolidated results have been prepared by adjusting our historical results to include the Acquisition as if it occurred on January 1, 2013. These unaudited pro forma consolidated historical results were then adjusted for the following: • a net reduction in amortization expense during the three and six months ended June 30, 2014 due to decreased intangible assets recorded related to the acquisition, • a net reduction in interest expense during the three and six months ended June 30, 2014 as we did not acquire the existing debt from the acquisition offset by our interest expense on net borrowings under capital leases and notes payable, • a net reduction in depreciation expense during the three and six months ended June 30, 2014 due to decreased fixed asset values recorded related to the acquisition, • a net reduction in general and administrative expenses for the three and six months ended June 30, 2014 to remove the management fees from the private equity company, • a net reduction to adjust for the tax effect of the losses that were acquired which is based on an estimate of the state income taxes and federal alternate minimum tax which would not be required based on the losses for all periods. As noted above, the unaudited pro forma results of operations do not purport to be indicative of the actual results that would have been achieved by the combined company for the periods presented or that may be achieved by the combined company in the future.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE D — INTANGIBLE ASSETS Intangible assets as of June 30, 2015 and December 31, 2014 consisted of the following (in thousands): Amortization Period June 30, 2015 COST Accumulated Amortization Net Customer Relationships 156 months $ 1,930 $ 146 $ 1,784 Support Vector Machine (SVM) technology 108 months 500 185 315 Laboratory developed test (LDT) technology 164 months 1,482 361 1,121 Flow Cytometry and Cytogenetics technology 202 months 1,000 198 802 Total $ 4,912 $ 890 $ 4,022 Amortization Period December 31, 2014 COST Accumulated Amortization Net Customer Relationships 156 months $ 1,930 $ 71 $ 1,859 Support Vector Machine (SVM) technology 108 months 500 167 333 Laboratory developed test (LDT) technology 164 months 1,482 297 1,185 Flow Cytometry and Cytogenetics technology 202 months 1,000 165 835 Total $ 4,912 $ 700 $ 4,212 We recorded approximately $97,000 and $55,000 in straight-line amortization expense of intangibles in the three months ended June 30, 2015 and 2014, respectively. We recorded approximately $190,000 and $111,000 in straight-line amortization expense of intangibles in the six months ended June 30, 2015 and 2014, respectively. The Company recorded amortization expense from customer relationships as a general and administrative expense. We will continue to record the amortization of the Support Vector Machine (SVM) technology, the Laboratory developed tests (LDT) technology and the Flow Cytometry and Cytogenetics technology intangibles as a research and development expense until the time that we have products, services or cost savings directly attributable to these intangible assets that would require that it be recorded in cost of goods sold. The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of June 30, 2015 is as follows (in thousands): Year Ending December 31, Remainder of 2015 $ 186 2016 372 2017 372 2018 372 2019 372 2020 372 Thereafter 1,976 Total $ 4,022

Revenue Recognition and Contrac

Revenue Recognition and Contractual Adjustments	6 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Revenue Recognition and Contractual Adjustments	NOTE E — REVENUE RECOGNITION AND CONTRACTUAL ADJUSTMENTS The Company recognizes revenues when (a) the price is fixed or determinable, (b) persuasive evidence of an arrangement exists, (c) the service is performed and (d) collectability of the resulting receivable is reasonably assured. The Company’s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent, and revenues are recognized once the diagnostic services have been performed, and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including Medicare, commercial insurance companies, other directly billed healthcare institutions such as hospitals and clinics, and individuals. The Company reports revenues from contracted payers, including Medicare, certain insurance companies and certain healthcare institutions, based on the contractual rate, or in the case of Medicare, published fee schedules. The Company reports revenues from non-contracted payers, including certain insurance companies and individuals, based on the amount expected to be collected. The difference between the amount billed and the amount estimated to be collected from non-contracted payers is recorded as an allowance to arrive at the reported net revenues. The expected revenues from non-contracted payers are based on the historical collection experience of each payer or payer group, as appropriate. The Company records revenues from patient pay tests net of a large discount and as a result recognizes minimal revenue on those tests. The Company regularly reviews its historical collection experience for non-contracted payers and adjusts its expected revenues for current and subsequent periods accordingly. The table below shows the adjustments made to gross service revenue to arrive at net revenues (in thousands), the amount reported on our statements of operations. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Gross service revenues $ 56,702 $ 57,805 $ 110,333 $ 99,004 Total contractual adjustments and discounts (32,332 ) (37,135 ) (62,937 ) (60,152 ) Net revenues $ 24,370 $ 20,670 $ 47,396 $ 38,852

Equity

Equity	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Equity	NOTE F — EQUITY Stock Options On May 4, 2015 the Board of Directors amended the Amended and Restated Equity Incentive Plan (Amended and Restated Effective as of April 16, 2013) (the “Plan”) to add an additional 2,500,000 shares to the maximum aggregate number of shares of Common Stock reserved and available for issuance under the Plan, bringing the total available from the Plan to 9,500,000 shares. On May 4, 2015 the Compensation Committee of the Board of Directors granted 1,645,000 options to certain Executives and key employees of the Company. The options were granted at a price of $4.78 per share and had a weighted average fair market value of $1.80 per option for a total fair market value of $2,961,000. A summary of the stock option activity under the Company’s plans for the six months ended June 30, 2015 is as follows: Number of shares Weighted Options outstanding at December 31, 2014 4,012,096 $ 2.04 Options granted 1,723,500 4.77 Less: Options exercised 207,625 1.54 Options canceled or expired 5,000 2.48 Options outstanding at June 30, 2015 5,522,971 2.91 Exercisable at June 30, 2015 2,739,622 $ 1.51 As of June 30, 2015, there was approximately $3.7 million of total unrecognized share-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.5 years. Stock-based compensation expense recognized for stock options and restricted stock and included in the consolidated statements of operations was allocated as follows: Three months ended June 30, Six months ended June 30, (in thousands) 2015 2014 2015 2014 Research and development expense $ 123 $ 27 $ 178 $ 69 General and administrative expense 385 130 635 177 Total stock-based compensation expense $ 508 $ 157 $ 813 $ 246 Common Stock Warrants A summary of the warrant activity for the six months ended June 30, 2015 is as follows: Number shares Weighted Warrants outstanding at December 31, 2014 650,000 $ 1.48 Warrants granted — — Less: Warrants exercised — — Warrants canceled or expired — — Warrants outstanding at June 30, 2015 650,000 1.48 Exercisable at June 30, 2015 530,000 $ 1.49 During the three months ended June 30, 2015 and 2014, we recorded $111,000 and $40,000 of warrant compensation expense, respectively. During the six months ended June 30, 2015 and 2014, we recorded $207,000 and $35,000 of warrant compensation expense, respectively. Restricted Stock Awards On April 16, 2015 the Company granted four directors of the Company each 2,080 shares of restricted stock. Such restricted stock will vest ratably over each of the next four quarters so long as the director still serves as a member of the Board of Directors. The fair market value of each grant of restricted stock on the award date was deemed to be $10,025 or $4.82 per share, which was the closing price of the Company’s common stock on the day before the grant was approved by the compensation committee of the Board of Directors. On June 16, 2015 the Company granted two directors of the Company each 1,560 shares of restricted stock. Such restricted stock will vest ratably over each of the next three quarters so long as the director still serves as a member of the Board of Directors. The fair market value of each grant of restricted stock on the award date was deemed to be $9,079 or $5.82 per share, which was the closing price of the Company’s common stock on the day before the grant was approved by the compensation committee of the Board of Directors.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE G — COMMITMENTS During the six months ended June 30, 2015, the Company entered into agreements with Wells Fargo Equipment Finance to lease approximately $1.5 million of laboratory and computer equipment. One lease agreement for approximately $0.2 million includes a 36 month term with a $1 buyout option at the end of the term and an interest rate of 3.61%. The other lease agreement for approximately $1.3 includes a 60 month term with a $1 buyout option at the end of term and an interest rate of 4.08%. The Company accounted for these lease agreements as capital leases. During the six months ended June 30, 2015, the Company entered into agreements with several vendors to lease for approximately $1.9 million of computer equipment and computer software. The leases have 36 month terms with $1 buyout options at the end of the terms and interest rates ranging between 4.00% and 13.5% with a weighted average interest rate of 5.47%. The Company accounted for these lease agreements as capital leases.

Other Related Party Transaction

Other Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Other Related Party Transactions	NOTE H — OTHER RELATED PARTY TRANSACTIONS During the three months ended June 30, 2015 and 2014, Steven C. Jones, a director of the Company, earned approximately $65,000 and $65,000, respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance. During the six months ended June 30, 2015 and 2014, Mr. Jones earned approximately $130,000 and $127,500, respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance. Mr. Jones also received $77,500 and $47,500 during the six months ended June 30, 2015 and 2014 as payment of his annual bonus compensation for the previous fiscal years, respectively. On May 4, 2015 the Company granted Steven C. Jones 225,000 stock options. The options were granted at a price of $4.78 per share and had a weighted average fair market value of $1.80 per option. The options vest ratably over the next three years.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2015
Summary of Final Amounts for Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the final amounts for the fair values of the assets acquired and liabilities assumed at the acquisition date of July 8, 2014 (in thousands): July 8, 2014 Current assets, including cash and cash equivalents $ 1,722 Property, plant and equipment 577 Identifiable intangible assets – customer relationships 1,930 Long term deposits 28 Goodwill 2,929 Total assets acquired 7,186 Current liabilities (1,180 ) Long-term liabilities (98 ) Net assets acquired $ 5,908
Estimated Amortization Expense	The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of June 30, 2015 is as follows (in thousands): Year Ending December 31, Remainder of 2015 $ 185 2016 371 2017 371 2018 371 2019 371 2020 371 Thereafter 1,982 Total $ 4,022
Summary of Unaudited Pro-forma Information	The following unaudited pro forma information (in thousands) have been provided for illustrative purposes only and are not necessarily indicative of results that would have occurred had the Acquisition been in effect since January 1, 2013, nor are they necessarily indicative of future results. Three Months Ended Six Months Ended Revenue $ 23,216 $ 43,833 Net (loss) (100 ) (406 ) (Loss) per share Basic $ (0.00 ) $ (0.01 ) Diluted $ (0.00 ) $ (0.01 )
Path Logic [Member]
Estimated Amortization Expense	The estimated amortization expense related to the acquired intangible assets for each of the five succeeding fiscal years and thereafter as of June 30, 2015 is as follows (in thousands): Year Ending December 31, Remainder of 2015 $ 74 2016 148 2017 148 2018 148 2019 148 2020 148 Thereafter 970 Total $ 1,784

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Classes of Intangible Assets	Intangible assets as of June 30, 2015 and December 31, 2014 consisted of the following (in thousands): Amortization Period June 30, 2015 COST Accumulated Amortization Net Customer Relationships 156 months $ 1,930 $ 146 $ 1,784 Support Vector Machine (SVM) technology 108 months 500 185 315 Laboratory developed test (LDT) technology 164 months 1,482 361 1,121 Flow Cytometry and Cytogenetics technology 202 months 1,000 198 802 Total $ 4,912 $ 890 $ 4,022 Amortization Period December 31, 2014 COST Accumulated Amortization Net Customer Relationships 156 months $ 1,930 $ 71 $ 1,859 Support Vector Machine (SVM) technology 108 months 500 167 333 Laboratory developed test (LDT) technology 164 months 1,482 297 1,185 Flow Cytometry and Cytogenetics technology 202 months 1,000 165 835 Total $ 4,912 $ 700 $ 4,212

Revenue Recognition and Contr16

Revenue Recognition and Contractual Adjustments (Tables)	6 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Adjustment of Transactions Revenue	The table below shows the adjustments made to gross service revenue to arrive at net revenues (in thousands), the amount reported on our statements of operations. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Gross service revenues $ 56,702 $ 57,805 $ 110,333 $ 99,004 Total contractual adjustments and discounts (32,332 ) (37,135 ) (62,937 ) (60,152 ) Net revenues $ 24,370 $ 20,670 $ 47,396 $ 38,852

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Stock Option Activity	A summary of the stock option activity under the Company’s plans for the six months ended June 30, 2015 is as follows: Number of shares Weighted Options outstanding at December 31, 2014 4,012,096 $ 2.04 Options granted 1,723,500 4.77 Less: Options exercised 207,625 1.54 Options canceled or expired 5,000 2.48 Options outstanding at June 30, 2015 5,522,971 2.91 Exercisable at June 30, 2015 2,739,622 $ 1.51
Summary of Stock-Based Compensation Expense Recognized for Stock Options and Restricted Stock Included in Consolidated Statements of Operations	Stock-based compensation expense recognized for stock options and restricted stock and included in the consolidated statements of operations was allocated as follows: Three months ended June 30, Six months ended June 30, (in thousands) 2015 2014 2015 2014 Research and development expense $ 123 $ 27 $ 178 $ 69 General and administrative expense 385 130 635 177 Total stock-based compensation expense $ 508 $ 157 $ 813 $ 246
Summary of Warrant Activity	A summary of the warrant activity for the six months ended June 30, 2015 is as follows: Number shares Weighted Warrants outstanding at December 31, 2014 650,000 $ 1.48 Warrants granted — — Less: Warrants exercised — — Warrants canceled or expired — — Warrants outstanding at June 30, 2015 650,000 1.48 Exercisable at June 30, 2015 530,000 $ 1.49

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($)	Jul. 08, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Amortization expense of intangibles		$ 97,000	$ 55,000	$ 190,000	$ 111,000
Path Logic [Member]
Business Acquisition [Line Items]
Business acquisition purchase price	$ 5,908,000
Amortization expense of intangibles		37,000		74,000
Acquired intangible assets	$ 1,930,000
Intangible asset amortization period	13 years
Goodwill expected tax deductible amount		$ 3,700,000		$ 3,700,000
Amortization Period				15 years

Acquisitions - Summary of Estim

Acquisitions - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jul. 08, 2014
Business Acquisition [Line Items]
GOODWILL	$ 2,929	$ 2,929
Path Logic [Member]
Business Acquisition [Line Items]
Current assets, including cash and cash equivalents			$ 1,722
Property, plant and equipment			577
Identifiable intangible assets - customer relationships			1,930
Long term deposits			28
GOODWILL			2,929
Total assets acquired			7,186
Current liabilities			(1,180)
Long-term liabilities			(98)
Net assets acquired			$ 5,908

Acquisitions - Estimated Amorti

Acquisitions - Estimated Amortization Expense (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Remainder of 2015	$ 186
2,016	372
2,017	372
2,018	372
2,019	372
2,020	372
Thereafter	1,976
Total	4,022	$ 4,212
Path Logic [Member]
Finite-Lived Intangible Assets [Line Items]
Remainder of 2015	74
2,016	148
2,017	148
2,018	148
2,019	148
2,020	148
Thereafter	970
Total	$ 1,784

Acquisitions - Summary of Unaud

Acquisitions - Summary of Unaudited Pro-forma Information (Detail) - Jun. 30, 2014 - Path Logic [Member] - USD ($) $ / shares in Units, $ in Thousands	Total	Total
Business Acquisition [Line Items]
Revenue	$ 23,216	$ 43,833
Net (loss)	$ (100)	$ (406)
(Loss) per share
Basic	$ 0	$ (0.01)
Diluted	$ 0	$ (0.01)

Intangible Assets - Classes of

Intangible Assets - Classes of Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
COST	$ 4,912	$ 4,912
Accumulated Amortization	890	700
Total	$ 4,022	$ 4,212
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	156 months	156 months
COST	$ 1,930	$ 1,930
Accumulated Amortization	146	71
Total	$ 1,784	$ 1,859
Support Vector Machine (SVM) Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	108 months	108 months
COST	$ 500	$ 500
Accumulated Amortization	185	167
Total	$ 315	$ 333
Laboratory Developed Test (LDT) Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	164 months	164 months
COST	$ 1,482	$ 1,482
Accumulated Amortization	361	297
Total	$ 1,121	$ 1,185
Flow Cytometry and Cytogenetics Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	202 months	202 months
COST	$ 1,000	$ 1,000
Accumulated Amortization	198	165
Total	$ 802	$ 835

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangibles	$ 97	$ 55	$ 190	$ 111

Intangible Assets - Estimated A

Intangible Assets - Estimated Amortization Expense (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2015	$ 186
2,016	372
2,017	372
2,018	372
2,019	372
2,020	372
Thereafter	1,976
Total	$ 4,022	$ 4,212

Revenue Recognition and Contr25

Revenue Recognition and Contractual Adjustments - Adjustment of Transactions Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue Recognition [Abstract]
Gross service revenues	$ 56,702	$ 57,805	$ 110,333	$ 99,004
Total contractual adjustments and discounts	(32,332)	(37,135)	(62,937)	(60,152)
Net revenues	$ 24,370	$ 20,670	$ 47,396	$ 38,852

Equity - Additional Information

Equity - Additional Information (Detail)	Jun. 16, 2015USD ($)Directors$ / sharesshares	May. 04, 2015USD ($)$ / sharesshares	Apr. 16, 2015USD ($)Directors$ / sharesshares	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)$ / shares	Jun. 30, 2014USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grant date price | $ / shares						$ 4.77
Unrecognized stock-based compensation cost				$ 3,700,000		$ 3,700,000
Unrecognized share-based compensation expense, weighted-average recognition period						1 year 6 months
Stock compensation expense						$ 813,000	$ 246,000
Amended and Restated Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized for issuance | shares		2,500,000
Aggregate number of shares available for issuance | shares		9,500,000
Amended and Restated Equity Incentive Plan [Member] | Certain Executives and Key Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grant date price | $ / shares		$ 4.78
Options, weighted average fair market value | $ / shares		$ 1.80
Options, number granted | shares		1,645,000
Options granted, fair market value		$ 2,961,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense				$ 111,000	$ 40,000	$ 207,000	$ 35,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of directors | Directors	2		4
Restricted Stock [Member] | Director One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock granted | shares	1,560		2,080
Fair market value restricted stock	$ 9,079		$ 10,025
Restricted stock price per share | $ / shares	$ 5.82		$ 4.82
Restricted Stock [Member] | Director Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock granted | shares	1,560		2,080
Fair market value restricted stock	$ 9,079		$ 10,025
Restricted stock price per share | $ / shares	$ 5.82		$ 4.82
Restricted Stock [Member] | Director Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock granted | shares			2,080
Fair market value restricted stock			$ 10,025
Restricted stock price per share | $ / shares			$ 4.82
Restricted Stock [Member] | Director Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock granted | shares			2,080
Fair market value restricted stock			$ 10,025
Restricted stock price per share | $ / shares			$ 4.82

Equity - Summary of Stock Optio

Equity - Summary of Stock Option Activity (Detail) - Jun. 30, 2015 - $ / shares	Total
Equity [Abstract]
Stock options, beginning balance	4,012,096
Stock options, granted	1,723,500
Stock options, exercised	207,625
Stock options, canceled or expired	5,000
Stock options, ending balance	5,522,971
Stock options, exercisable, ending balance	2,739,622
Weighted average exercise price, beginning balance	$ 2.04
Weighted average exercise price, granted	4.77
Weighted average exercise price, exercised	1.54
Weighted average exercise price, canceled or expired	2.48
Weighted average exercise price, ending balance	2.91
Weighted average exercise price, exercisable, ending balance	$ 1.51

Equity - Summary of Stock-Based

Equity - Summary of Stock-Based Compensation Expense Recognized for Stock Options and Restricted Stock Included in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 508	$ 157	$ 813	$ 246
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	123	27	178	69
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 385	$ 130	$ 635	$ 177

Equity - Summary of Warrant Act

Equity - Summary of Warrant Activity (Detail) - Jun. 30, 2015 - Warrant [Member] - $ / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, beginning balance	650,000
Warrants granted	0
Warrants exercised	0
Warrants canceled or expired	0
Warrants outstanding, ending balance	650,000
Warrants exercisable, ending balance	530,000
Weighted average exercise price, warrants outstanding, beginning balance	$ 1.48
Weighted average exercise price, warrants granted	0
Weighted average exercise price, warrants exercised	0
Weighted average exercise price, warrants canceled or expired	0
Weighted average exercise price, warrants outstanding, ending balance	1.48
Weighted average exercise price, warrants exercisable, ending balance	$ 1.49

Commitments - Additional Inform

Commitments - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Contractual Obligation [Line Items]
Agreement for purchase of equipment	$ 3,400,000	$ 3,321,000
Laboratory and Computer Equipment [Member] | Wells Fargo Equipment Finance [Member]
Contractual Obligation [Line Items]
Agreement for purchase of equipment	1,500,000
Laboratory and Computer Equipment [Member] | Wells Fargo Equipment Finance [Member] | 36 Month Term [Member]
Contractual Obligation [Line Items]
Agreement for purchase of equipment	$ 200,000
Lease term period	36 months
Buyout option	$ 1
Interest rate	3.61%
Laboratory and Computer Equipment [Member] | Wells Fargo Equipment Finance [Member] | 60 Month Term [Member]
Contractual Obligation [Line Items]
Agreement for purchase of equipment	$ 1,300,000
Lease term period	60 months
Buyout option	$ 1
Interest rate	4.08%
Other Lease Agreement [Member] | Computer Equipment and Computer Software [Member]
Contractual Obligation [Line Items]
Agreement for purchase of equipment	$ 1,900,000
Buyout option	$ 1
Weighted average interest rate	5.47%
Minimum [Member] | Other Lease Agreement [Member] | Computer Equipment and Computer Software [Member]
Contractual Obligation [Line Items]
Lease term period	36 months
Interest rate	4.00%
Maximum [Member] | Other Lease Agreement [Member] | Computer Equipment and Computer Software [Member]
Contractual Obligation [Line Items]
Interest rate	13.50%

Other Related Party Transacti31

Other Related Party Transactions - Additional Information (Detail) - USD ($)	May. 04, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Related Party Transaction [Line Items]
Options, grant date price				$ 4.77
Executive Vice President [Member]
Related Party Transaction [Line Items]
Fees for consulting work performed		$ 65,000	$ 65,000	$ 130,000	$ 127,500
Payment of annual bonus compensation				$ 77,500	$ 47,500
Options, grant date price	$ 4.78
Options, number granted	225,000
Options, weighted average fair market value	$ 1.80
Options, vesting period	3 years